Pharmacy Department, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Intern Med J. 2011 Jan;41(1b):121-9. doi: 10.1111/j.1445-5994.2010.02343.x.
Although the incidence of neutropenic fever (FN) is estimated to be up to 80% for some malignancies, the epidemiological characteristics and economic burden are not well understood for Australian patients.
To describe underlying malignant conditions, potential aetiologies, clinical outcomes and healthcare utilization for an Australian population with FN, and to estimate the economic burden of this condition within the Australian healthcare sector.
Epidemiological features of FN were extracted from a population-based hospital morbidity dataset, the Victorian Admitted Episodes Dataset (VAED), for a 12-month period (2008). These were analysed according for a range of malignancy categories. Economic burden of hospitalizations was estimated according to data presented in the Round 12 National Hospital Cost Data Collection Report.
A total of 2599 admitted episodes across 92 Victorian hospitals fulfilled inclusion criteria for FN. Metropolitan hospitalizations accounted for 79% episodes. FN illness comprised underlying solid tumours diagnoses (40%), followed by leukaemia (29.3%), lymphoma (22%) and myeloma (8.5%). Length of hospital stay was >15 days for approximately one-third of hospitalizations. intensive care unit admission rates were 5.9-11.7%. Weighted average costs of hospitalization (AUD) for solid tumours, lymphoma, myeloma and leukaemia were $8309 ± $391, 18,145 ± $1602, $21,764 ± $1289 and $22,596 ± $2618 respectively.
Using VAED indices, epidemiological features of Australian patients with FN appear comparable with international reports. In contrast to US data, estimated healthcare costs are up to 50% lower in the Australian healthcare sector. These data offer important insights for prioritizing of research agendas and resource allocation.
尽管某些恶性肿瘤的中性粒细胞减少性发热（FN）发病率估计高达 80%，但澳大利亚患者的流行病学特征和经济负担尚不清楚。
描述澳大利亚 FN 患者的潜在恶性疾病、潜在病因、临床结局和医疗保健利用情况，并估计澳大利亚医疗保健部门内该疾病的经济负担。
从基于人群的医院发病率数据集——维多利亚州入院事件数据集（VAED）中提取 FN 的流行病学特征，时间为 12 个月（2008 年）。根据一系列恶性肿瘤类别对这些特征进行了分析。根据第 12 轮国家医院成本数据收集报告中提供的数据，估算了住院的经济负担。
共有 2599 例符合 FN 纳入标准的住院患者来自 92 家维多利亚州医院。大都市的住院患者占 79%。FN 疾病包括潜在的实体瘤诊断（40%），其次是白血病（29.3%）、淋巴瘤（22%）和骨髓瘤（8.5%）。大约三分之一的住院患者的住院时间超过 15 天。重症监护病房的入院率为 5.9-11.7%。实体瘤、淋巴瘤、骨髓瘤和白血病的住院平均加权费用（澳元）分别为 8309 澳元±391 澳元、18145 澳元±1602 澳元、21764 澳元±1289 澳元以及 22596 澳元±2618 澳元。
使用 VAED 指数，澳大利亚 FN 患者的流行病学特征似乎与国际报告相似。与美国的数据相比，澳大利亚医疗保健部门的估计医疗保健成本低 50%。这些数据为确定研究议程和资源分配的优先级提供了重要的见解。
